Litcius/Paper detail

All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial

Qiu-Sha Huang, Yi Liu, Jingbo Wang, Jun Peng, Ming Hou, Hui Liu, Ru Feng, Jingwen Wang, Lan‐Ping Xu, Yang Wang, Xiao‐Jun Huang, Xiaohui Zhang

2021The Lancet Haematology33 citationsDOI

Topics & Concepts

MedicineImmune thrombocytopeniaOpen labelDexamethasoneRetinoic acidInternal medicineClinical trialPediatricsPlateletChemistryGeneBiochemistryPlatelet Disorders and TreatmentsRetinoids in leukemia and cellular processesRenal Diseases and Glomerulopathies
All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial | Litcius